{
    "clinical_study": {
        "@rank": "131266", 
        "acronym": "TEAM ASV-I", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology alone"
            }, 
            {
                "arm_group_label": "Adaptive servo-ventilation", 
                "arm_group_type": "Active Comparator", 
                "description": "optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology plus treatment of sleep apnea with adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia). Dose: The optimal ASV settings will be determined during 1-2 nights monitored by polygraphy within 5 days after PCI."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this randomized controlled trial is to test the effect of 12 weeks Adaptive\n      Servo-Ventilation (ASV) therapy (additionally to optimal medical management of myocardial\n      infarction) on myocardial salvage (MSI=myocardial salvage/area at risk, primary endpoint)."
        }, 
        "brief_title": "ASV for Sleep Apnea After Myocardial Infarction", 
        "condition": [
            "Acute Myocardial Infarction", 
            "Sleep Apnea"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Apnea", 
                "Infarction", 
                "Myocardial Infarction", 
                "Sleep Apnea Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. age 18-80 years\n\n          2. first AMI (ST-elevation in ECG or acute occlusion of coronary artery)\n\n          3. Primary successful PCI achieved <24 h after symptom onset\n\n          4. SA with an AHI >=15 per hour recording time\n\n          5. written informed consent\n\n        Exclusion criteria:\n\n          1. previous myocardial infarction\n\n          2. previous myocardial revascularization (PCI or surgical)\n\n          3. indication for a surgical revascularisation\n\n          4. cardiogenic shock, mean supine blood pressure <60mmHg or NYHA class IV\n\n          5. implanted cardiac device or other contraindications for CMR\n\n          6. known allergies or other contraindication to contrast medium (e.g.\n             GFR<30ml/min/1.73m\u00b2)\n\n          7. history of stroke\n\n          8. contraindications for positive airway pressure support (hypotension with mean supine\n             BP <60mmHg, dehydration, inability to clear secretions, patients at risk for\n             aspiration of gastric contents, severe bullous lung disease, history of pneumothorax\n             and/or pneumomediastinum, a history of epistaxis, causing pulmonary aspiration of\n             blood, cerebrospinal fluid leak or recent skull operations or injury) patients on or\n             with indication for oxygen therapy, mechanical/non-invasive ventilation\n\n          9. patients on nocturnal positive airway pressure support\n\n         10. severe obstructive or restrictive airway disease\n\n         11. heart failure due to primary valve disease\n\n         12. patients awaiting heart transplantation\n\n         13. diurnal symptoms of OSA requiring immediate treatment\n\n         14. pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093377", 
            "org_study_id": "Protocol Version 6.0"
        }, 
        "intervention": {
            "arm_group_label": "Adaptive servo-ventilation", 
            "description": "Adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia)", 
            "intervention_name": "Adaptive servo-ventilation", 
            "intervention_type": "Device", 
            "other_name": "ASV"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "acute myocardial infarction", 
            "sleep apnea", 
            "adaptive servo-ventilation"
        ], 
        "lastchanged_date": "March 20, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Olaf Oldenburg, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bad Oeynhausen", 
                        "country": "Germany", 
                        "zip": "32545"
                    }, 
                    "name": "Herz- und Diabeteszentrum NRW"
                }, 
                "investigator": {
                    "last_name": "Olaf Oldenburg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Leonhard Bruch, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "12683"
                    }, 
                    "name": "Unfallkrankenhaus Berlin"
                }, 
                "investigator": {
                    "last_name": "Leonhard Bruch, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sven Meyer, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Oldenburg", 
                        "country": "Germany", 
                        "zip": "26133"
                    }, 
                    "name": "Klinikum Oldenburg"
                }, 
                "investigator": {
                    "last_name": "Sven Meyer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "michael.arzt@ukr.de", 
                    "last_name": "Michael Arzt, MD", 
                    "phone": "+49 941 944 7281"
                }, 
                "facility": {
                    "address": {
                        "city": "Regensburg", 
                        "country": "Germany", 
                        "zip": "93053"
                    }, 
                    "name": "University Hospital Regensburg"
                }, 
                "investigator": [
                    {
                        "last_name": "Michael Arzt, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Stefan Buchner, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Kurt Debl, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Andrea Hetzenecker, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment of Sleep Apnea Early After Myocardial Infarction With Adaptive Servo-Ventilation - a Randomized Controlled Trial", 
        "overall_contact": {
            "email": "michael.arzt@ukr.de", 
            "last_name": "Michael Arzt, MD", 
            "phone": "+49 941 944 7281"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Regensburg", 
            "last_name": "Michael Arzt, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To test the effect of 12 weeks of ASV (additionally to percutaneous coronary intervention, PCI, and optimal medical management of AMI) on myocardial salvage (myocardial salvage index, MSI, assessed by cardiovascular magnetic resonance imaging, CMR).", 
            "measure": "myocardial salvage index, MSI", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093377"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital Regensburg", 
            "investigator_full_name": "Michael Arzt", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To test whether ASV therapy in patients with SA early after AMI decreases infarct size and improves left ventricular remodelling (myocardial salvage, microvascular obstruction change of infarct size, infarct size at 12 weeks, change of left ventricular ejection fraction (LVEF), left ventricular systolic volume (LVSV), left ventricular diastolic volume (LVDV) and LVEF at 12 weeks; assessed with CMR).", 
                "measure": "infarct size and left ventricular remodelling", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To test whether ASV therapy in patients with SA early after AMI reduces B-type natriuretic peptide (NT-proBNP).", 
                "measure": "B-type natriuretic peptide (NT-proBNP)", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To test whether ASV therapy in patients with SA early after AMIimproves disease specific symptom burden (Seattle Angina Questionnaire)", 
                "measure": "disease specific symptom burden", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To test whether ASV therapy in patients with sleep apnea early after AMI suppresses sleep apnea (apneas and hypopneas/hour of sleep, mean oxygen saturation).", 
                "measure": "suppresses sleep apnea", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "increases renal function (Glomerular Filtration Rate, calculated using the 4vMDRD formula).", 
                "measure": "renal function", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "University Hospital Regensburg", 
        "sponsors": {
            "collaborator": {
                "agency": "ResMed Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University Hospital Regensburg", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}